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Abstract Our objective was to assess the 5-year cost
effectiveness of bronchodilator therapy with tiotropi-
um, salmeterol or ipratropium for chronic obstructive
pulmonary disease (COPD) from the perspective of
the Spanish National Health System (NHS). A prob-
abilistic Markov model was designed wherein patients
moved between moderate, severe or very severe
COPD and had the risk of exacerbation and death.
Probabilities were derived from clinical trials. Spanish
healthcare utilisation, costs and utilities were estimated
for each COPD and exacerbation state. Outcomes
were exacerbations, exacerbation-free months, quality-
adjusted life years (QALYs), and cost(-effectiveness).
The mean (SE) 5-year number of exacerbations was
3.50 (0.14) for tiotropium, 4.16 (0.40) for salmeterol
and 4.71 (0.54) for ipratropium. The mean (SE) num-
ber of QALYs was 3.15 (0.08), 3.02 (0.15) and 3.00
(0.20), respectively. Mean (SE) 5-year costs were
e6,424 (e305) for tiotropium, e5,869 (e505) for
salmeterol, and e5,181 (e682) for ipratropium (2005
values). Ipratropium and tiotropium formed the cost-
effectiveness frontier, with tiotropium being preferred
when willingness to pay (WTP) exceeded e639 per
exacerbation-free month and e8,157 per QALY. In
Spain, tiotropium demonstrated the highest expected
net beneﬁt for ratios of the willingness to pay per
QALY, well within accepted limits.
Keywords Chronic obstructive pulmonary disease
(COPD)  Bronchodilators  Model  Cost
effectiveness  Quality-adjusted life year (QALY) 
Spain
Abbreviations
CE-plane Cost-effectiveness plane
COPD Chronic obstructive pulmonary
disease
ER Emergency room
EQ-5D EuroQol 5-dimension utility
measurement instrument
FEV1 % pred. Forced expiratory volume in 1 s as
percentage of the predicted value
ml Millilitres
SE Standard error
QALY Quality-adjusted life year
UK United Kingdom
VAT Value added tax
Introduction
Owing to the chronic progressing nature and increasing
prevalence of chronic obstructive pulmonary disease
(COPD),itstreatmentwillundoubtedlyincreasepressure
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DOI 10.1007/s10198-007-0039-4on the drug budgets of developed countries in the
future. Several new and competing treatments for
COPD have recently been introduced, or may soon
become available [1]. Healthcare authorities will be
forced to decide upon reimbursement of these medica-
tionsandwillrequirehigh-qualityinformationaboutthe
costs and effectiveness of these new drugs. Pharmaco-
economic evaluations provide this information and may
guide the positioning of new drugs in the treatment
spectrum of COPD.
To date, most economic evaluations of pharmaco-
therapy for COPD have been conducted alongside
randomised controlled trials [2–7]. Consequently, their
time horizon has been restricted to the duration of
these trials, which is usually 6 months to 1 year, al-
though economic evaluations of inhaled bronchodila-
tors and corticosteroids piggybacked to clinical trials
with durations of only 12–16 weeks have been reported
[4, 5]. For reimbursement authorities and formulary
decision makers, these short-term economic evalua-
tions are of limited value, because COPD requires
long-term maintenance treatment on a daily basis.
Furthermore, these policy makers will need results that
represent their national or regional setting. Because it
is not feasible to conduct long-term empirical cost-
effectiveness studies in all potential markets, some sort
of modelling is required. This will allow expansion of
the time horizon beyond that of a clinical trial, as well
as the adapting and transferring of results from one
setting to another. Decision analytical modelling has
become an accepted approach to economic evalua-
tions, and the use of modelling is supported by nearly
all pharmaco-economic guidelines issued by health
authorities involved in decision making about pricing
and reimbursement of new pharmaceuticals, including
Spain [8–11].
This study investigates the cost effectiveness of three
bronchodilators for the maintenance treatment of
COPD in Spain: tiotropium, salmeterol and ipratropi-
um. Bronchodilators are central to the symptomatic
management of COPD. Bronchodilators include three
classes of medications: (1) the inhaled beta2-agonists,
(2) the inhaled anticholinergics and (3) the oral
methylxanthines. All three classes include drugs that
are short acting or long acting. The most recently
launched bronchodilator is tiotropium, an anticholin-
ergic that provides 24 h bronchodilation with once-
daily dosing. It was developed as a more effective and
more convenient alternative to ipratropium, the most
frequently used short-acting anticholinergic bron-
chodilator in COPD, which has to be used four times
daily. At the time tiotropium became available,
salmeterol, which is used twice daily, was the most
effective and the most frequently used long-acting
bronchodilator from the beta2-agonists class. Orally
administered methylxanthines, such as theophylline,
are not recommended for routine use due to their
unfavourable risk/beneﬁt ratios. In a series of multi-
national trials tiotropium was directly compared with
either placebo [12], ipratropium [13] or salmeterol [14].
The above-mentioned clinical trials have shown that
tiotropium provides sustained bronchodilation, reduces
exacerbation rate, and improves dyspnoea and health-
related quality of life when compared with placebo or
ipratropium. Improvements in lung function have been
shown to be signiﬁcantly better with tiotropium than
with salmeterol [14]. Because information on the long-
term cost effectiveness of these bronchodilators is
lacking, a decision analytical model was developed to
determine the 5-year cost effectiveness of tiotropium,
salmeterol and ipratropium for the treatment of COPD.
Efﬁcacy data were derived from the above-mentioned
clinical trials, and the potential cost effectiveness of
inhaledbronchodilator therapy was assessed inscenario
analyses. The model was populated with Spanish
epidemiological data on COPD, Spanish healthcare
utilisation, and unit costs and utilities based on
Spanish population values. Spain was chosen because
cost-effectiveness data on bronchodilator therapy from
a Southern European country were lacking.
Methods
The model
This 5-year model can be characterised as a Markov
model [15]. It builds on our earlier work in which
we constructed a fully probabilistic Markov model to
assess the 1-year cost effectiveness of tiotropium,
salmeterol and ipratropium [16, 17]. All mathematical
and technical details of this 1-year model have been
published elsewhere [17]. In brief, all COPD patients
were classiﬁed into three disease states of increasing
severity, based on their pre-bronchodilator forced
expiratory volume in 1 s (FEV1): moderate COPD
(50% £ the percentage of the predicted value (FEV1 %
pred.) < 80%), severe COPD (30% £ FEV1 % pred.
< 50%) and very severe COPD (FEV1 %p r e d .<3 0 % ) .
In pre-speciﬁed time intervals (Markov cycles) patients
move between disease states and are at risk of expe-
riencing an exacerbation, either severe or non-severe.
All probabilities to move between disease states
(transition probabilities) and to experience exacerba-
tions that went into the 1-year model were obtained
directly from six clinical trials comparing tiotropium
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123with salmeterol, ipratropium or placebo (study codes:
205.114/205.117, 205.115/205.128, 205.122A/205.126A,
205.122B/205.126B, 205.130 and 205.137) [12–14].
Transition probabilities and exacerbation probabilities
for tiotropium were based on the pooled patient-level
data from all six clinical trials. To obtain the transition
and exacerbation probabilities for the comparator
arms, we applied the relative difference between tiot-
ropium and the comparators in the individual trials to
the probabilities of tiotropium that were derived from
the pooled data [17].
All trials used similar inclusion and exclusion
criteria. They enrolled patients with stable moderate-
to-severe COPD who had an FEV1 < 65% (salmeterol-
controlled trials < 60%) of predicted normal and
FEV1 £ 70% of forced vital capacity. The duration of
these trials was 1 year for the those that compared
tiotropium with placebo and ipratropium and 6 months
for the trials that compared tiotropium with salmeterol.
In total, 1,308 patients were randomly allocated to re-
ceive tiotropium, and 771 patients, 405 patients, and
179 patients were randomly selected to receive pla-
cebo, salmeterol and ipratropium. In all trials the same
deﬁnitions of an exacerbation and its severity were
used. An exacerbation was deﬁned as a new onset or
worsening of more than one symptom, such as cough,
sputum, dyspnoea or wheeze, lasting for at least 3 days.
Exacerbations were distinguished into severe and non-
severe exacerbations. A severe exacerbation was de-
ﬁned as ‘incapacitating or inability to do work or usual
activity’. All other exacerbations were non-severe.
Severity was assessed by the clinical investigator. The
risk of experiencing an exacerbation varied by disease
state and treatment group. Given treatment group and
disease state, exacerbation probabilities were assumed
to be constant over time [17].
The current model expanded the time horizon from
1 year to 5 years and aimed to assess the cost effec-
tiveness of tiotropium, salmeterol and ipratropium for
treating COPD patients in Spain. To reﬂect the pro-
gressive nature of COPD in the long run and to
incorporate mortality, an additional ‘death state’ was
added to the model. The base-case analysis was per-
formed from the perspective of the Spanish National
Health Service (NHS) and included all costs covered
by the NHS budget in euros at the 2005 value. A
graphical presentation of the 5-year model is given in
Fig. 1. In addition, an analysis from the societal per-
spective was performed. The difference between the
societal perspective and the NHS perspective was that
the ﬁrst additionally included patients’ co-payments for
medications and the costs of lost production from
day 1 of sick leave onwards; however, it excluded value
added tax (VAT), as this does not represent a cost to
society.
Scenarios
The ﬁrst year of the model incorporated the beneﬁts of
therapy as observed in the clinical studies for
improvement in lung function, which delayed the
progression to subsequent COPD severity states [17].
The ﬁrst year of the model also incorporated the
reduction in the number of exacerbations that were
found in the clinical trials [17]. These ﬁrst year prob-
abilities are shown in the upper part of Table 1 and in
Table 2. Because the clinical trials did not provide data
on the probabilities to move between disease states
and to experience exacerbations after the ﬁrst year, the
5-year model was used to run three scenarios with
different assumptions on transition and exacerbation
probabilities for years 2 to 5:
1. In the base-case scenario, the decline in FEV1 after
the ﬁrst year was assumed to be 52 ml/year [18]i n
all treatment groups, whereas the exacerbation
probabilities remained as they were for the ﬁrst
year. The decline of 52 ml was the mean annual
change in FEV1 among smokers and ex-smokers in
the Lung Health Study [18]. The lower part of
Table 1 shows the transition probabilities in the
base-case scenario during years 2 to 5, whereas
Table 2 shows the exacerbation probabilities.
Moderate COPD 
+ or - 
exacerbation 
Severe COPD 
+ or - 
exacerbation 
Very severe COPD 
+ or –  
exacerbation 
Death
Fig. 1 Graphical presentation of the Markov model. Backward
transitions, i.e. from very severe to severe COPD and from
severe to moderate COPD, were allowed during the ﬁrst year,
but not thereafter. The circles on the top left of each COPD
severity state indicate that the patients can stay in the same state
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1232. In the second scenario, both transition and exac-
erbation probabilities of the ﬁrst year were as-
sumed to remain constant during years 2 to 5. In
other words, the ﬁrst year probabilities as shown in
Table 1 (under the heading ‘‘Subsequent cycle
probabilities, year 1’’) and 2 were applied to the
later years.
3. In the third scenario, it was assumed that disease
progression and exacerbation risk no longer dif-
fered between treatment groups after the ﬁrst year.
Exacerbation probabilities for tiotropium, salme-
terol and ipratropium were assumed to be equal to
the ﬁrst year probabilities of the ipratropium group
(columns 4 and 7 of Table 2). The assumption on
lung function decline was the same as in the base-
case scenario.
Note that the three scenarios do not differ with
respect to the ﬁrst year. During the ﬁrst year, both
forward transitions (transitions to worse disease states)
and backward transitions (transitions to better disease
states) are possible. In the base-case and third scenario,
backward transitions during years 2 to 5 were not al-
lowed, reﬂecting the progressive nature of COPD in
general. Further note that no differences between
treatments in terms of mortality risk were assumed.
Input data: baseline distribution of patients among
disease states
The baseline distribution of patients among the disease
states was based on a Spanish study by Miravitlles
et al. [19] Re-analysis of the data according to the
severity deﬁnition used in the model showed that, of
436 COPD patients, 55.2% had moderate disease,
34.9% had severe disease and 9.9% had very severe
disease. A disease state for mild COPD was not in-
cluded in the model, because mild COPD patients did
not participate in the tiotropium trials.
Input data: death state
Probabilities of dying were based on all-cause mortal-
ity rates among Spanish patients with severe or very
severe COPD as published by Miravitlles et al. [20].
The data from this study were re-analysed using the
same cut-off values for the FEV1% predicted of severe
and very severe COPD that were used in the model.
The 1-year all-cause mortality rate was found to be 25
per 1,000 among patients with severe COPD [20], and
the relative mortality risk in patients with very severe
COPD compared with severe COPD was found to be
4.96 for a mean decline in FEV1% predicted of 19.4%.
T
a
b
l
e
1
M
e
a
n
(
S
E
)
p
r
o
b
a
b
i
l
i
t
i
e
s
t
o
m
o
v
e
b
e
t
w
e
e
n
d
i
s
e
a
s
e
s
t
a
t
e
s
i
n
t
h
e
b
a
s
e
-
c
a
s
e
s
c
e
n
a
r
i
o
.
(
T
h
e
s
e
p
r
o
b
a
b
i
l
i
t
i
e
s
w
e
r
e
a
l
s
o
u
s
e
d
i
n
s
c
e
n
a
r
i
o
3
.
I
n
s
c
e
n
a
r
i
o
2
t
h
e
s
u
b
s
e
q
u
e
n
t
c
y
c
l
e
p
r
o
b
a
b
i
l
i
t
i
e
s
f
o
r
y
e
a
r
1
w
e
r
e
a
p
p
l
i
e
d
t
o
y
e
a
r
s
2
t
o
5
.
T
h
e
c
y
c
l
e
l
e
n
g
t
h
w
a
s
8
d
a
y
s
f
o
r
t
h
e
v
e
r
y
ﬁ
r
s
t
c
y
c
l
e
a
n
d
1
m
o
n
t
h
f
o
r
o
f
a
l
l
s
u
b
s
e
q
u
e
n
t
c
y
c
l
e
s
)
T
o
 
F
r
o
m
 
T
i
o
t
r
o
p
i
u
m
S
a
l
m
e
t
e
r
o
l
I
p
r
a
t
r
o
p
i
u
m
M
o
d
e
r
a
t
e
S
e
v
e
r
e
V
e
r
y
s
e
v
e
r
e
D
e
a
t
h
M
o
d
e
r
a
t
e
S
e
v
e
r
e
V
e
r
y
s
e
v
e
r
e
D
e
a
t
h
M
o
d
e
r
a
t
e
S
e
v
e
r
e
V
e
r
y
s
e
v
e
r
e
D
e
a
t
h
F
i
r
s
t
c
y
c
l
e
p
r
o
b
a
b
i
l
i
t
i
e
s
M
o
d
e
r
a
t
e
0
.
9
0
6
(
0
.
0
1
8
)
0
.
0
9
2
(
0
.
0
1
8
)
0
.
0
0
1
(
0
.
0
0
2
)
0
.
0
0
1
(
0
.
0
0
1
)
0
.
8
9
8
(
0
.
0
3
3
)
0
.
1
0
0
(
0
.
0
3
3
)
0
.
0
0
1
(
0
.
0
0
3
)
0
.
0
0
1
(
0
.
0
0
1
)
0
.
7
3
8
(
0
.
0
9
2
)
0
.
2
5
7
(
0
.
0
9
1
)
0
.
0
0
4
(
0
.
0
1
3
)
0
.
0
0
1
(
0
.
0
0
2
)
S
e
v
e
r
e
0
.
2
5
9
(
0
.
0
1
7
)
0
.
7
1
5
(
0
.
0
1
8
)
0
.
0
2
5
(
0
.
0
0
6
)
0
.
0
0
1
(
0
.
0
0
1
)
0
.
2
0
1
(
0
.
0
2
8
)
0
.
7
6
5
(
0
.
0
3
0
)
0
.
0
3
3
(
0
.
0
1
3
)
0
.
0
0
1
(
0
.
0
0
2
)
0
.
1
0
2
(
0
.
0
2
8
)
0
.
8
4
1
(
0
.
0
3
4
)
0
.
0
5
6
(
0
.
0
2
2
)
0
.
0
0
1
(
0
.
0
0
2
)
V
e
r
y
s
e
v
e
r
e
0
.
0
1
0
(
0
.
0
0
5
)
0
.
3
4
0
(
0
.
0
2
4
)
0
.
6
4
8
(
0
.
0
2
4
)
0
.
0
0
2
(
0
.
0
0
2
)
0
.
0
0
1
(
0
.
0
0
3
)
0
.
3
0
1
(
0
.
0
4
2
)
0
.
6
9
6
(
0
.
0
4
2
)
0
.
0
0
2
(
0
.
0
0
4
)
0
.
0
0
5
(
0
.
0
1
1
)
0
.
2
2
0
(
0
.
0
6
6
)
0
.
7
7
3
(
0
.
0
6
7
)
0
.
0
0
2
(
0
.
0
0
7
)
S
u
b
s
e
q
u
e
n
t
c
y
c
l
e
p
r
o
b
a
b
i
l
i
t
i
e
s
,
y
e
a
r
1
M
o
d
e
r
a
t
e
0
.
9
5
7
(
0
.
0
1
0
)
0
.
0
4
0
(
0
.
0
1
0
)
0
.
0
0
3
(
0
.
0
0
3
)
0
.
0
0
1
(
0
.
0
0
1
)
0
.
9
2
9
(
0
.
0
2
5
)
0
.
0
6
6
(
0
.
0
2
4
)
0
.
0
0
5
(
0
.
0
0
7
)
0
.
0
0
1
(
0
.
0
0
2
)
0
.
9
2
4
(
0
.
0
5
0
)
0
.
0
7
3
(
0
.
0
4
9
)
0
.
0
0
3
(
0
.
0
1
0
)
0
.
0
0
1
(
0
.
0
0
4
)
S
e
v
e
r
e
0
.
0
2
3
(
0
.
0
0
6
)
0
.
9
5
2
(
0
.
0
0
9
)
0
.
0
2
3
(
0
.
0
0
6
)
0
.
0
0
2
(
0
.
0
0
2
)
0
.
0
2
3
(
0
.
0
1
1
)
0
.
9
1
6
(
0
.
0
2
0
)
0
.
0
5
9
(
0
.
0
1
7
)
0
.
0
0
2
(
0
.
0
0
3
)
0
.
0
1
3
(
0
.
0
1
1
)
0
.
9
4
8
(
0
.
0
2
1
)
0
.
0
3
7
(
0
.
0
1
8
)
0
.
0
0
2
(
0
.
0
0
4
)
V
e
r
y
s
e
v
e
r
e
0
.
0
0
1
(
0
.
0
0
2
)
0
.
0
4
5
(
0
.
0
1
2
)
0
.
9
4
7
(
0
.
0
1
3
)
0
.
0
0
8
(
0
.
0
0
5
)
0
.
0
0
6
(
0
.
0
0
8
)
0
.
0
3
6
(
0
.
0
1
9
)
0
.
9
5
1
(
0
.
0
2
3
)
0
.
0
0
8
(
0
.
0
0
9
)
0
.
0
0
3
(
0
.
0
0
9
)
0
.
0
2
5
(
0
.
0
2
6
)
0
.
9
6
4
(
0
.
0
3
1
)
0
.
0
0
8
(
0
.
0
1
5
)
S
u
b
s
e
q
u
e
n
t
c
y
c
l
e
p
r
o
b
a
b
i
l
i
t
i
e
s
,
y
e
a
r
s
2
t
o
5
M
o
d
e
r
a
t
e
0
.
9
8
4
(
0
.
0
0
7
)
0
.
0
1
5
(
0
.
0
0
7
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
1
(
0
.
0
0
1
)
0
.
9
8
1
(
0
.
0
1
7
)
0
.
0
1
9
(
0
.
0
1
7
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
1
(
0
.
0
0
3
)
0
.
9
7
8
(
0
.
0
3
3
)
0
.
0
2
2
(
0
.
0
3
3
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
1
(
0
.
0
0
5
)
S
e
v
e
r
e
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
9
0
(
0
.
0
0
4
)
0
.
0
0
8
(
0
.
0
0
3
)
0
.
0
0
2
(
0
.
0
0
2
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
8
7
(
0
.
0
0
8
)
0
.
0
1
1
(
0
.
0
0
7
)
0
.
0
0
2
(
0
.
0
0
3
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
8
6
(
0
.
0
1
2
)
0
.
0
1
1
(
0
.
0
1
1
)
0
.
0
0
2
(
0
.
0
0
5
)
V
e
r
y
s
e
v
e
r
e
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
9
2
(
0
.
0
0
5
)
0
.
0
0
8
(
0
.
0
0
5
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
9
2
(
0
.
0
0
7
)
0
.
0
0
8
(
0
.
0
0
7
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
0
0
0
(
0
.
0
0
0
)
0
.
9
9
2
(
0
.
0
1
1
)
0
.
0
0
8
(
0
.
0
1
1
)
126 M. P. M. H. Rutten-van Mo ¨lken et al.
123Under the assumption of constant proportional
hazards, the relative mortality risk of patients in the
trials was estimated to be 3.754 for very severe COPD
and 0.248 for moderate COPD compared with severe
COPD. We applied these relative risks to the all-cause
mortality rate of 25 per 1,000 among patients with
severe COPD to derive the mortality rates and, subse-
quently, the probabilities of dying, among patients with
moderate and very severe COPD. These probabilities
were the same for all treatment groups.
Input data: utilities
To reﬂect the impaired quality of life of patients with
COPD, we attached utility weights to each disease
severity state. These utilities were obtained from the
EQ-5D scores at baseline in a subset of patients ran-
domly accepted into the UPLIFT trial (n = 1,133) [21].
These scores were valued using the Spanish tariff [22].
A value of 1 represents perfect health, whereas 0
represents death. Mean (SE) utilities at baseline of
the UPLIFT trial were calculated to be 0.809 (0.008)
in patients with moderate disease, 0.762 (0.009) in
patients with severe disease and 0.655 (0.024) in
patients with very severe disease. During the months
in which patients experienced an exacerbation, the
utility value was reduced by 15% in the case of a non-
severe exacerbation [23] and by 50% in the case of a
severe exacerbation [24]. Each year, the number of
quality-adjusted life-years (QALYs) was calculated as
the sum of the multiplications of the number of months
in a particular disease state and the utility of that
disease state, divided by 12.
Input data: costs
The details and results of the cost estimates are pre-
sented in Table 3. Estimates of healthcare utilisation
were primarily derived from two studies performed in
Spain that had measured resource use and costs of the
treatment of patients with COPD [25, 26]. Data from
these studies were re-analysed to estimate resource use
and costs by disease severity and exacerbation severity,
using similar deﬁnitions as applied in the model. In the
model, healthcare utilisation associated with COPD
maintenance therapy varied by disease severity.
Healthcare utilisation during exacerbations varied by
the severity of the exacerbation (severe or non-severe).
Calculations were conservative in assuming that costs
per disease severity state and costs per severe or non-
severe exacerbation were equal across treatment
groups. Resources for maintenance therapy included
visits to respiratory physicians inside and outside the
hospital, visits to the general practitioner, pulmonary
function tests, blood tests, imaging tests and respiratory
medications. Resources associated with a non-severe
exacerbation included general practitioner and respi-
ratory physician visits and medications. Besides phy-
sician visits and outpatient medications, resources
associated with severe exacerbations also included
hospital admissions and visits to the emergency room
(ER) department. Costs of pulmonary function and
other tests, as well as costs of medications that were
prescribed during inpatient stay or during ER visits,
were not measured separately, because they were in-
cluded in the overall costs per in-patient day and the
costs per ER visit.
Unit costs of healthcare resources were obtained
from the SOIKOS health database and have been de-
scribed in detail elsewhere [25]. They were updated to
2005 using the Spanish General Consumer Price Index.
Acquisition costs of pulmonary drugs from the NHS
perspective were based on public prices and calculated
as the ex-factory prices multiplied by a mark-up of
1.596 to convert these prices to public prices [27]. The
co-payment of 10% of the public price for the people in
the work force was excluded. It was estimated that
33.2% of Spanish COPD patients had to pay these co-
payments because they were still in the work force [27].
From a societal perspective, the drug costs included co-
payment but excluded the 4% VAT that is included in
the public prices. Costs of tiotropium, salmeterol and
ipratropium from the NHS perspective were e1.80,
e1.20 and e0.19 per day, respectively. From the soci-
Table 2 Mean (SE) exacerbation probabilities in the base-case scenario. (These probabilities were also used in scenario 2. In
scenario 3 the probabilities of ipratropium were also applied to tiotropium and salmeterol during years 2 to 5)
Probability of experiencing an exacerbation Probability that the exacerbation will be severe, given that
there is an exacerbation
Tiotropium Salmeterol Ipratropium Tiotropium Salmeterol Ipratropium
Moderate 0.051 (0.004) 0.057 (0.013) 0.080 (0.020) 0.097 (0.024) 0.030 (0.031) 0.267 (0.114)
Severe 0.075 (0.003) 0.089 (0.011) 0.097 (0.013) 0.136 (0.018) 0.138 (0.033) 0.188 (0.041)
Very severe 0.096 (0.005) 0.104 (0.016) 0.102 (0.022) 0.192 (0.027) 0.207 (0.048) 0.186 (0.062)
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e1.18 for salmeterol and e0.18 for ipratropium.
The NHS covers the costs of absence from work due
to illness from the 16th day of sick leave onwards. The
NHS pays 60% of gross salary during days 16 to 20 and
75% from day 21 onwards. When we were calculating
costs from the NHS perspective, these costs were ad-
ded to the costs of all severe exacerbations with sick
leave longer than 15 days (approximately 7% of all
severe exacerbations). The costs from the societal
perspective included the costs of lost production during
all days of absence from paid work.
The resulting mean (SE) annual costs of mainte-
nance therapy from an NHS perspective were e430
(e24) for a patient with moderate COPD, e587 (e34)
for a patient with severe COPD and e818 (e58) for a
patient with very severe COPD. The corresponding
values from the societal perspective were e429 (e21),
e586 (e34) and e816 (e58). The mean (SE) costs
of exacerbations from the NHS perspective were
Table 3 Mean healthcare utilisation (HU), unit costs, and mean
(SE) total costs of maintenance therapy and exacerbations from
the NHS perspective for Spain in euros at the 2005 value (HU
healthcare utilisation, RP respiratory physician, GP general
practitioner, ICU intensive care unit, exa exacerbation)
Maintenance therapy Unit
costs
Moderate COPD Severe COPD Very severe COPD
HU per patient
per year
Total
costs
HU per patient
per year
Total
costs
HU per patient
per year
Total
costs
Visit RP in hospital 79.85 0.27 22 (1) 0.44 35 (2) 0.63 50 (3)
Visit RP outside hospital 23.77 0.38 9 (1) 0.57 14 (1) 0.65 15 (1)
Visit GP 8.35 2.59 22 (1) 2.88 24 (1) 3.27 27 (1)
Thorax X-ray 19.67 1.03 20 (1) 1.18 23 (1) 1.49 29 (1)
ECG 22.53 0.80 18 (1) 0.87 20 (1) 1.15 26 (1)
Spirometry 40.63 0.55 22 (1) 0.66 27 (1) 0.92 37 (2)
Blood analyses 19.67 1.41 28 (1) 1.43 28 (1) 1.58 31 (1)
Blood gases 27.25 0.33 9 (1) 0.56 15 (1) 0.67 18 (1)
Inﬂuenza vaccination 5.47 0.48 3 (1) 0.64 4 (1) 0.72 4 (1)
Theophylline 0.18 122.06 22 (8) 161.77 30 (4) 159.07 29 (5)
Mucolytics 0.30 39.74 11 (3) 48.31 14 (2) 80.60 24 (4)
Oral corticosteroids 0.29 21.54 6 (3) 23.73 7 (1) 78.48 23 (6)
Inhaled corticosteroids 0.61 224.84 138 (12) 224.84 138 (15) 292.00 179 (22)
Oxygen 3.73 21.32 79 (14) 44.26 165 (30) 77.87 290 (52)
Other 20 (3) 44 (4) 34 (5)
Total costs per patient per year 430 (24) 587 (34) 818 (58)
Exacerbations Unit
costs
Non-severe exacerbation Severe exacerbation Study medication costs per day
HU per exa Total costs HU per exa Total costs
ICU
a 1,284 – – 0.29 374 (291) Tiotropium 1.80
Non-ICU
a 368 – – 4.16 1,529 (307) Salmeterol 1.20
Emergency room 115 – – 0.94 108 (11) Ipratropium 0.19
Visit GP 8.35 1.64 14 (1) 1.00 8 (3)
Visit RP in hospital 79.85 – – 0.52 42 (10)
Antibiotics
b 5.00 11.02 55 (7) 7.52 38 (7)
Oral corticosteroids
b 0.29 2.69 1 (1) 4.98 1 (1)
Inhaled corticosteroids
b 0.61 7.01 4 (1) 3.71 2 (1)
Oxygen
b 3.73 2.05 8 (3) 5.32 20 (2)
Other 1 (1) 1 (1)
NHS sick leave beneﬁt
c 74.09 13 (2)
Total costs per exacerbation 83 (7) 2,136 (425)
For medications and oxygen HU is expressed in number of days during which the medication or oxygen was used
a Of all severe exacerbations 52% required hospital admission. Of those, 14% were to the ICU. The length of stay on ICU is 4 days,
and the length of stay on non-ICU is 8 days. Hence, 0.52 · 0.14 · 4 = 0.29 and 0.52 · 8 = 4.16
b Only medications prescribed in ambulatory settings. Costs of medications administered in hospital and at emergency rooms are
included in costs of hospital stay/emergency room visit
c Average labour costs per day in Spain are e74.09. Of Spanish COPD patients, 33.2% have paid employment; 0.332 ·
e74.09 = e24.60. The NHS covers 60% of these labour costs during days 16–20 of the sick leave episode and 75% from day 21
onwards. Of severe exacerbations, 7% are associated with sick leave longer than 15 days. The duration of these absence spells is
26 days. So, (5 · 0.6 · e24.60 + 6 · 0.75 · e24.60) · 0.07 = e13.43
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(e425) for a severe exacerbation. From a societal
perspective these costs were e121 (e7) and e3,912
(e543), respectively.
COPD severity
To investigate the impact of COPD severity on the cost
effectiveness of the bronchodilators we ran sensitivity
analyses with the base-case scenario, assuming that, at
the start of the model, 100% of the patients had either
moderate, severe or very severe COPD.
Discounting
Because of time preference, costs and effects that will
arise in the future are usually valued lower than costs
and effects in the present. Discounting is used to cal-
culate the present value of future costs and effects. In
accordance with proposed Spanish guidelines, an
annual discount rate of 6% has been adopted [28]. In
the base-case analysis, costs and health outcomes were
discounted at the same rate, whereas, in sensitivity
analyses, discount rates of 0% for both costs and
effects, and 6% for costs combined with 3% for effects,
were applied. In scenarios 2 and 3 the same 6% dis-
count rate was used as in the base-case scenario.
Probabilistic sensitivity analysis
To facilitate the interpretation of results of economic
analyses, the reporting of uncertainty associated with
costs and outcomes is equally important as reporting
the point estimates of these parameters. Hence, the
model was designed fully probabilistic, and uncertainty
around the probabilities to move between disease
states, the probabilities to experience exacerbations,
utilities and healthcare utilisation was addressed by
deﬁning a probability distribution for each input
parameter [17]. The uncertainty around these input
parameters was propagated through the model simul-
taneously by conducting second-order Monte Carlo
simulations. This means making random draws of the
uncertain parameters from their probability distribu-
tion, running the model for each set of parameters that
is drawn, and collecting the outputs from each run [29].
The current results were based on 5,000 iterations.
The main outcome measures of the model were
mean and standard error (SE, being the standard
deviation of the 5,000 iterations) of the 5-year costs per
patient, exacerbation-free months and quality-adjusted
life years. The presentation of incremental cost effec-
tiveness was based on the hierarchy of outcomes, i.e.
each treatment option was compared with the next best
treatment option in terms of effectiveness. The
uncertainty around costs and effects was further ex-
plored by plotting of the 5,000 iterations on incre-
mental cost-effectiveness planes (CE-planes) [30] and
by presenting cost-effectiveness acceptability curves
[30, 31] and frontiers [32]. The acceptability curve
presents the probability that a treatment is the most
cost effective of the three treatments at different
threshold values for cost effectiveness (ceiling ratio),
whereas the cost-effectiveness acceptability frontier
demonstrates which of the three treatments should be
adopted because it results in the highest expected net
beneﬁt, given the ceiling ratio. The net beneﬁt is cal-
culated as the total costs (C) minus the effects (E)
multiplied by the ceiling ratio (C –( E · ceiling ratio))
[33]. The model was programmed in Microsoft
EXCEL.
Results
Health outcomes
The results of the Markov simulation for the different
scenarios are presented in Table 4. In the base-case
scenario, the mean (SE) number of exacerbations in
5 years was 3.50 (0.14) in the tiotropium group, 4.16
(0.40) in the salmeterol group and 4.71 (0.54) in the
ipratropium group. The corresponding mean (SE)
number of exacerbation-free months was 46.83 (1.11)
in the tiotropium group, 45.29 (2.12) in the salmeterol
group and 44.89 (2.86) in the ipratropium group. Esti-
mates of the number (SE) of QALYs were 3.15 (0.08),
3.02 (0.15) and 3.00 (0.20), respectively. In all scenar-
ios, differences in exacerbation-free months and
QALYs between treatment groups were consistently in
favour of the tiotropium group. Applying the ﬁrst
year probabilities to all subsequent years (scenario 2)
increased the difference in exacerbation-free months
between tiotropium and the other treatment groups to
approximately 2.0 and the difference in QALYs to
approximately 0.19. Assuming similar exacerbation
probabilities across treatment groups in year 2 to 5
(scenario 3) reduced the differences between treatment
groups considerably. In this analysis, the difference in
exacerbation-free months between tiotropium and the
other treatment groups was just above 1, and the dif-
ference in QALYs was about 0.13. There was almost
no difference in health outcomes between ipratropium
and salmeterol in this scenario.
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In the base-case scenario from the NHS perspective,
mean (SE) total costs over 5 years were lowest in the
ipratropium group, with e5,181 (e682) per patient
(Table 4). Costs were e5,869 (e505) in the salmeterol
group and e6,424 (e305) in the tiotropium group.
The higher costs in the tiotropium and salmeterol
Table 4 Results of the Markov simulation for the base-case
analysis from the NHS perspective covering a time period of
5 years. The table gives mean (SE) or mean (95% confidence
interval). QALY quality-adjusted life year, Tio tiotropium, Salm
salmeterol, Ipra Ipratropium, exa exacerbations, CE-ratio cost-
effectiveness ratio, exa-free exacerbation-free
Outcomes base-case analysis (cumulative over 5 years)
Health outcome  Tiotropium  Salmeterol Ipratropium
Exacerbations   3.50 (0.14)  4.16 (0.40)  4.71 (0.54) 
Exacerbation-free months  46.83 (1.11)  45.29 (2.12)  44.89 (2.86) 
Life-years  4.19 (0.10)  4.12 (0.19)  4.13 (0.26) 
QALYs  3.15 (0.08)  3.02 (0.15)  3.00 (0.20) 
Costs in 2005 Euro mean (SE)
Costs of exacerbations 1289 (231) 1558 (374) 2335 (584)
Costs of maintenance therapy 2380 (114) 2514 (183) 2558 (238)
Costs of study medications  2757 (65)  1801 (83)  279 (18)
Total costs  6424 (305) 5869 (505) 5181 (682)
Differences and incremental cost-effectiveness ratios per scenario 
Base-case scenario 
Differences in: Tio versus salm Salm versus Ipra 
 Exacerbation-free months  1.54 (-2.50; 6.81)   0.40 (-6.26; 7.99) 
 QALYs  0.14 (-0.16; 0.49)  0.02 (-0.43; 0.53) 
Costs 555  (-647;  1651)  688 (-1012; 2291) 
Incremental CE-ratios 
 Cost per exa-free month  360  1711
18% 65% 35% 46%  Quadrant distribution 
 CE-plane exa-free month  8% 9 % 13% 6 % 
 Cost per QALY  4118 38931 
15% 68% 37% 44%   Quadrant distribution 
 CE-plane QALY  5% 12% 13% 6 % 
Scenario 2 
Differences in: Tio versus salm Salm versus Ipra 
 Exacerbation-free months  1.93 (-2.58; 8.62)   0.21 (-7.86; 9.77) 
 QALYs  0.19 (-0.12; 0.63)  0.002 (-0.54; 0.63) 
Costs 418  (-869;  1692)  758 (-1151; 2541) 
Incremental CE-ratios 
 Cost per exa-free month  217  3698
 Cost per QALY 2239 348971
Scenario 3 
Differences in: Tio versus Salm Salm versus Ipra 
 Exacerbation-free months  1.07 (-3.02; 6.46)    -0.008 (-6.54; 8.00) 
 QALYs  0.13 (-0.16; 0.49)  0.001 (-0.45; 0.55) 
Costs 831  (-860;  2489)  1205 (-648; 3066) 
Incremental CE-ratios 
 Cost per exa-free month  777  -144075
 Cost per QALY 6446 15635 690861
130 M. P. M. H. Rutten-van Mo ¨lken et al.
123group were largely due to the higher costs of study
medication. Compared with those of ipratropium, the
5-year costs of study medication were e2,477 (e67)
higher in the tiotropium group and e1,521 (e85)
higher in the salmeterol group. Savings in other cat-
egories of costs, mainly exacerbation-related costs,
offset approximately half of these additional study
medication costs.
Because of a smaller difference in exacerbation rate
between treatment groups in scenario 3, the difference
in total costs between ipratropium on the one hand and
tiotropium and salmeterol on the other hand increased
by 64% and 75%, respectively. The impact of applying
the ﬁrst-year transition probabilities to years 2 to 5
(scenario 2) on the 5-year differences in costs between
treatment groups was much less (Table 4).
Cost effectiveness
In the base-case scenario from the NHS perspective
estimates of the incremental costs per exacerbation-
free month were e360, when tiotropium was compared
with salmeterol, and e1,711 when salmeterol was
compared with ipratropium. The corresponding incre-
mental costs per QALY were e4,118 and e38,931,
respectively. The distribution of the results of the 5,000
model iterations on the CE-planes is also reported in
Table 4. The comparisons between tiotropium and
salmeterol show that the majority of simulations
(approximately 65%) lie in the upper-right quadrants,
signifying better health outcomes and higher costs for
tiotropium. The CE-planes comparing salmeterol with
ipratropium show that about 35% of the dots are found
in the upper-left and about 45% in the upper-right
quadrant, signifying similar health outcomes and
higher costs for salmeterol.
Figure 2 shows the cost-effectiveness acceptability
curves in the base-case scenario from the NHS per-
spective. The curves show that, in terms of exacerba-
tion-free months, ipratropium has the highest
probability of being cost effective when the threshold
value for cost per additional exacerbation-free month
is below e1,050. In terms of QALYs, ipratropium has
the highest probability of being the most cost effective
for all threshold values for cost per QALY below
e11,000. Above these values, tiotropium has the
highest probability of being cost effective. However,
when the distribution of the cost-effectiveness ratio is
skewed, as is the case in the presented analyses, the
treatment with the highest probability of being cost
effective is not always the treatment with the highest
expected net beneﬁt [32]. In Fig. 2, the cost-effective-
ness acceptability frontier is drawn in bold. The fron-
tier follows the curve of the treatment with the highest
expected net beneﬁt for a given value of the cost-
effectiveness threshold. Hence, it indicates which
treatment should be chosen because it is optimal. The
bold curve demonstrates that both ipratropium and
tiotropium are on the frontier. For any ceiling ratio
above e639 per exacerbation-free month and above
e8,157 per QALY, tiotropium is the preferred treat-
ment option. In scenario 2, these threshold values were
lower: e551 and e6,226, respectively, whereas the
corresponding values in scenario 3 were e1,918 and
e15,635. The point on the frontier where the most
optimal treatment switches from ipratropium to tiot-
ropium in Fig. 2 corresponds to the base-case incre-
mental cost-effectiveness ratio for the comparison
between these two bronchodilators. Figure 2 also
shows that, although tiotropium has the highest prob-
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Fig. 2 Cost-effectiveness acceptability curves and frontier of the
costs per exacerbation-free month and the cost per QALY.
Ceiling ratio: threshold value for the cost-effectiveness ratio in
euros. The curves in grey represent the probability that a
treatment is cost effective for a given value of the ceiling ratio. In
the case of skewed distributions of the ratio, the treatment with
the highest probability of being cost effective is not always the
treatment with the highest expected net beneﬁt. The acceptabil-
ity frontier (in black) shows which treatment is associated with
the highest expected net beneﬁt for each value of the ceiling ratio
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123ability of being the most optimal treatment, this
probability is 58% at maximum. This 58% is the value
at which the acceptability curve of tiotropium using
QALYs becomes asymptotic.
Societal perspective
From the societal perspective, overall mean (SE) costs
increased in all treatment groups to e6,574 (e321) for
tiotropium, e6,125 (e541) for salmeterol and e5,545
(e720) for ipratropium. However, the savings in
exacerbation costs generated by tiotropium and
salmeterol compared with ipratropium were higher
from a societal perspective than from the NHS per-
spective. Consequently, from the societal perspective,
the difference in overall costs between the treatment
groups was reduced. Also, the incremental costs per
exacerbation-free month were reduced to e308, for the
comparison tiotropium versus salmeterol, and e1,375
for the comparison salmeterol versus ipratropium. The
incremental cost per QALY were reduced to e3,483,
for the comparison tiotropium versus salmeterol, and
e35,158 for the comparison salmeterol versus ipratro-
pium. Tiotropium had the highest expected net beneﬁt
for any value of the cost-effectiveness threshold above
e547 per exacerbation-free month and above e7,076
per QALY. Below these values ipratropium is pre-
ferred.
Impact of COPD severity
When the model was run separately for patients with
either moderate, severe or very severe COPD, it
showed that the threshold value above which tiotro-
pium had the highest expected net beneﬁt increased
with the severity of COPD. The threshold values for
the costs per QALY above which tiotropium became
the preferred option were e7,600 for moderate COPD,
e8,800 for severe COPD and e12,500 for very severe
COPD. Below these values ipratropium was preferred.
Tiotropium had the highest expected net beneﬁt when
the ceiling ratios for cost per exacerbation free month
were e560 for moderate COPD, e700 for severe
COPD and e1,200 for very severe COPD. Below
these values ipratropium had the highest expected net
beneﬁt.
Discount rates
Because discounting affects both health outcomes and
costs, the effect of discounting in this study was small.
Analyses based ondiscount rates of 3% and0% showed
almost similar cost-effectiveness ratios. Discounting
health outcomes at a lower rate than costs led to cost-
effectiveness ratios that were slightly more in favour
of tiotropium.
Discussion
Bronchodilators form the main therapy for the symp-
tomatic relief of respiratory symptoms in COPD
patients. In this study we have constructed a decision
analytical model to synthesise clinical trial data on the
effectiveness of bronchodilator treatment. We have
shown how scenario analyses can be used to extend the
time horizon of the cost-effectiveness study beyond
that of the clinical trials. In addition, we have shown
how a model can be populated with country-speciﬁc
data to obtain estimates of the cost-effectiveness of
bronchodilators in the Spanish setting.
This comprehensive country adaptation and exten-
sion of the existing short-term Markov model [17] re-
quired much more than just the imputation of Spanish
unit costs. We searched for Spanish sources for almost
every type of input data, ranging from the distribution
of COPD severity stages, mortality, the proportion of
COPD patients in the work force, utilities, resource use
and unit costs. We re-analysed patient-level data from
previously published Spanish studies on prevalence,
mortality, EQ-5D, and resource utilisation [19–21, 25,
26] to ensure that these Spanish data matched the
model’s deﬁnitions of COPD severity and exacerbation
severity. This included obtaining point estimates as
well as distributions of these input data. The strength
of the Spanish data is also that mainly patients from
general practices were included, thus reﬂecting the
routine care setting closely. The majority of Spanish
patients are treated by general practitioners, and the
proportion of patients referred to specialist care by
pulmonologists is smaller than in many other west
European countries [34]. This may be related to the
gate-keeping function of the general practitioner in
Spain that is not enforced in some other European
countries.
The base-case scenario showed that tiotropium was
associated with an approximately 16% reduction in
exacerbations when compared with salmeterol.
Salmeterol was associated with 12% reduction in
exacerbations, when compared with ipratropium.
Differences between the three treatment groups in
terms of QALYs were small. That was expected, given
the 5-year time horizon and treatments that do not
directly affect survival. The distribution of dots on the
CE-planes showed that the higher effectiveness of
salmeterol over ipratropium was associated with more
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123uncertainty than the higher effectiveness of tiotropium
over salmeterol, because, for the latter comparison, a
larger proportion of the dots was found on the right
side of the CE plane.
Beside effectiveness, the choice between bronchod-
ilators must involve many considerations, including
economic considerations of costs and cost effective-
ness. The ﬁnal result of this cost-effectiveness analysis
is an acceptability frontier that demonstrated that
tiotropium has the highest expected net beneﬁt for a
threshold value of the costs per QALY that is well
within the limits of other adopted therapies in Spain
[35] and in other countries like the UK [36]. This
threshold value increases with the severity of COPD,
because the differences between treatments in the
probabilities of developing a (severe) exacerbation
decrease as COPD severity increases. Nevertheless,
the cost-effectiveness threshold in the most severely
affected patients is still relatively low.
The threshold value for costs per additional exacer-
bation-free month of e639 above which tiotropium
becomes the optimal choice in Spain is higher than the
ceiling ratios above which tiotropium became most cost
effective in the Netherlands (e0) and Canada (e10) in
the 1-year model [17]. Similarly, when QALYs were
used astheoutcomemeasure,theceilingratio ofe8,157
per QALY above which tiotropium is the preferred
option in Spain is also higher than in The Netherlands
and Canada, where tiotropium became the preferred
option when decision makers could afford to pay more
than e0 and e120 for a QALY, respectively. This
difference between these countries is largely driven by
the relatively low acquisition costs of ipratropium in
Spain, which is related to the fact that there is no
widespread use of the more expensive dry powder
formulation of ipratropium. In addition, the savings due
to the reduction in exacerbations by tiotropium and
salmeterolareless,becausethecostsoftreatingasevere
exacerbation in Spain are lower than in The Nether-
lands and Canada. This is caused by a smaller propor-
tion of patients hospitalised, as well as a shorter length
of stay. As a result, tiotropium generated very small net
savings in the Netherlands and similar costs to the other
two bronchodilators in Canada, whereas it increased
total costs in Spain. Nevertheless, in the three countries
investigated, the economic evaluations indicated that
the health beneﬁts gained with tiotropium are either at
almost no additional costs or at costs that appear rea-
sonable andacceptable, given other adopted treatments
[37, 38].
Our base-case scenario was conservative with
respect to lung function decline, as we assigned a similar
decline of 52 ml/year to the patients in all treatment
groups after the ﬁrst year. We chose this to be the best
assumption for the base-case scenario, because there is
little evidence in the literature that bronchodilators
alter the rate of decline of lung function [39]. However,
frequent exacerbations seem to accelerate the decline
in lung function [40, 41]. Therefore, our base-case
scenario might have underestimated the long-term
effect of a bronchodilator that reduces the number and
severity of exacerbations. For that reason, we devel-
oped the second scenario, which is the least conserva-
tive, because we assumed that the differences in lung
function decline and exacerbation rates between the
three treatments that were observed during the ﬁrst
year would remain during the 4 years thereafter. This
scenario is most favourable for tiotropium, and we see
the threshold value above which tiotropium becomes
most cost effective drop to e551 per exacerbation-free
month and e6,226 per QALY. In addition to this
optimistic scenario, we developed a very conservative
scenario by completely eliminating the difference in
exacerbation rate between the treatment groups after
the ﬁrst year and assuming that exacerbation rates
would resemble the rate observed in the ipratropium
group. This third scenario also assumed a similar de-
cline in lung function across treatment groups of 52 ml/
year. This third scenario is conservative because
exacerbations were the main drivers of cost effective-
ness. The threshold value above which tiotropium be-
comes most cost effective in this third scenario
increases to e1,918 for an additional exacerbation-free
month and e15,635 for a QALY, yet is still below
acceptable limits reported for the Spanish setting. Be-
low that, ipratropium was most cost effective. Alto-
gether, these three scenarios give the range within
which to expect the 5-year cost effectiveness of these
bronchodilators. Note, that we had no scenarios
assuming a differential effect of the treatments on, for
example, utilities or costs of a single exacerbation,
because the evidence of such effects is lacking. Fur-
thermore, all scenarios had a time horizon of 5 years to
meet the requirements of many European reimburse-
ment authorities who prefer extensions to time horizons
reﬂecting their budgeting process (typically for 3–
5 years).Lifetimemodelsthatprimarilyaimtocompare
medications are soon outdated by the development of
new therapeutic options.
When the cost-effectiveness analysis was conducted
from a societal perspective, the threshold value above
which tiotropium is the preferred option is reduced
considerably to e547 per exacerbation-free month and
e7,076 per QALY. This improved cost effectiveness is
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cause of the inclusion of the costs of production losses.
Hence, a reduced exacerbation rate is associated with
higher savings. The NHS perspective also included sick
leave beneﬁts paid for by the NHS from day 16 on-
wards. However, this applies only to severe exacerba-
tions where it was less than 1% of its costs. In contrast,
from a societal perspective, costs of production losses
are 10% of the costs of a severe exacerbation and 30%
of the costs of a non-severe exacerbation.
We chose two outcome measures that are among
the most relevant in the lives of patients with COPD:
being free of exacerbations and having a good quality
of life. The concept of an exacerbation-free month is
comparable to the concept of a symptom-free day,
which is a frequently used outcome measure in asth-
ma [42]. As it is a positive outcome (i.e. more is
better), its cost-effectiveness ratio is easier to interpret
than the ratio ‘cost per exacerbation avoided’. In
general, the number of exacerbations is not a good
outcome measure to use in long-term models, espe-
cially when treatment improves survival. This out-
come measure will bias the treatment which improves
survival, because patients can experience exacerba-
tions during the life years gained. In contrast, the
number of exacerbation-free months takes account of
the fact that the added years of life are partly lived
free of exacerbations.
The 1-year model, as well as the currently presented
long-term model, has been used in reimbursement
negotiations in several countries. The major strength of
this model is its transparency. We have fully disclosed
the model structure as well as all the input. Costs per
exacerbation and costs per disease state do not differ
between the three treatment groups, and mortality
rates by disease severity were also set equally for all
treatment groups. Hence, the difference in cost effec-
tiveness is driven by the difference in acquisition costs
of the study drugs and the difference in their effec-
tiveness, i.e. the difference in the probabilities to move
between disease states and the differences in exacer-
bation risks. For the ﬁrst year of the model, estimates
of effectiveness were directly obtained from patient-
level data from clinical trials. Hence, estimates of
probabilities were not based on expert opinion or lit-
erature, as is often the case in modelling studies. We
acknowledge that differences may exist between trial
results from which we derived the model input and the
effectiveness of therapy in routine daily practice. A
model can be used to adapt the trial data to better
represent daily practice. Particularly, compliance is
known to be worse in daily practice. However, not
accounting for compliance was conservative for
tiotropium and salmeterol, since once-daily and
twice-daily dosing is more likely to be accompanied
by long-term compliance than is four-times daily
dosing in chronic diseases [43]. Owing to the double-
blind, double-dummy design of the clinical trials, the
dosing frequency was the same in the treatment
groups, and any impact of dosing frequency on out-
comes was eliminated.
In conclusion, our model has demonstrated that
tiotropium is the treatment with the highest expected
net beneﬁt, if decision makers can afford to spend
additional budget to gain additional health beneﬁts.
The threshold value of the costs per QALY at which
tiotropium becomes the preferred treatment is well
within acceptable limits (i.e. e8,157 from the NHS
perspective and e7,076 from the societal perspec-
tive).
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